Nat Turner
Team Member @ First Round Capital
New York, United States
Nat Turner is a seed investor at First Round Capital in New York focused on Health Care and Software. Nat Turner is based out of New York, New York, and is the CEO and Chairman of Collectors. Nat previously worked at OneOncology as a board member. Nat Turner attended the Wharton School of the University of Pennsylvania.
- Total investments:
- 80
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Nat Turner invests in
Stages Nat Turner invests in
Countries Nat Turner invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.5M–$6.3M
- Series A
- $3M–$25M
- Series B
- $5M–$36M
Investment Focus
Industry
- Health Care 23 (29%)
- Software 22 (28%)
- Medical 12 (15%)
- SaaS 7 (9%)
- Artificial Intelligence 7 (9%)
Stage
- Seed 37 (46%)
- Series A 24 (30%)
- Series B 6 (8%)
- Pre-Seed 3 (4%)
- Funding Round 3 (4%)
Country
- United States 63 (79%)
- China 1 (1%)
- Colombia 1 (1%)
- New Zealand 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| CollX (pronounced “collects”) is the fastest way to figure out what your cards are worth. Snap photos of them and instantly get the current market price. The company was founded in 2021 and is headquartered in Haddonfield, New Jersey, United States. | $5.5M / Seed / Feb 22, 2023 | ||
| Collectors offers authentication and sale services for high-value collectibles. | $100M / Private Equity / Mar 30, 2022 | ||
| Oshi Health is a virtual-first gastroenterology (GI) clinic that diagnoses, treats and remotely monitors digestive (GI) conditions. Patients work with Oshi Health's integrated care team of gastroenterologists and GI-specialized nurse practitioners, registered dietitians, behavioral psychologists and health coaches to determine the root causesof their symptoms and use a personalized care plan that includes medication, dietary interventions and stress/anxiety reduction to get symptoms under control. This yields improved health outcomes, quality of life, satisfaction with care and workplace productivity while reducing overall healthcare cost. | $23M / Series A / Oct 12, 2021 | ||
| Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space. The company was founded in 2017 and is based in Cambridge, Massachusetts. | $30M / Series A / Aug 03, 2021 | ||
| Iterative Health is a healthcare technology and services company that focuses on accelerating clinical research to improve patient outcomes through innovative approaches. The company transforms gastrointestinal (GI) care by utilizing AI-driven clinical trials and diagnostics, significantly enhancing access to vital treatments. | $30M / Series A / Aug 03, 2021 | ||
| Connie Health empowers older Americans to make confident, worry-free healthcare decisions. | $13M / Series A / Jul 28, 2021 | ||
| Nym transforms revenue cycle management by fully automating the medical coding process. Our engine deciphers clinical language in patient charts and accurately assigns medical charge codes in seconds and with zero human intervention. By automating medical coding with Nym, healthcare providers can improve coding quality while significantlyreducing the time and cost associated with medical coding. This ultimately ensures clinical and administrative teams can spend more time focused on patient care. | $25M / Series B / Jul 27, 2021 | ||
| Loupe is a live eCommerce streaming platform developing a mobile application used to collect sports cards. Its application offers exciting new ways to buy, sell, invest, and collect sports cards that enable users to reinvent sports card games at a whole new level. The company was founded in 2020 and is headquartered in Miami, Florida. | $12M / Series A / Jun 10, 2021 | ||
| HumanFirst accelerates the adoption of patient-centered clinical trials using precision digital measures (e.g., digital biomarkers and eCOA).At HumanFirst, we offer a precision measures platform - the world’s largest AI-powered SaaS platform trusted to improve human outcomes. We provide insights, intelligence, and accuracy with validated evidencedata to precisely guide and accelerate human-centric drug development. Twenty-two of the 25 largest pharmaceutical companies in the world have used the HumanFirst platform to evaluate and enable the deployment of digital health technologies (DHTs). | $12M / Series A / May 31, 2021 | ||
| RightBound develops a sales platform that automates and streamlines the sales process. The platform does the leg-work for clients, instead of just providing data and insights, giving clients access to a new type of sales development platform. | $8.9M / Series A / May 26, 2021 | ||
| See all 80 investments → | |||
Co-Investors
About First Round Capital
First Round is a seed-stage venture firm focused on building a community of technology entrepreneurs and companies, including Uber, Square, and Warby Parker. Through custom-built software, incredible in-person experiences, and a host of other unique services, First Round helps tiny companies get big while constantly reimagining the role of venture capital. It offers a growing number of services and products to help founders build companies from scratch. First Round has adopted the Diversity Term Sheet Rider.
First Round Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amy Fu
VP, Investments
|
|||
Elliot Cohen
Angel Track
|
|||
Emery Rosansky
VP, Revenue Growth and Enablement
|
|||
Akins Van Horne
Angel Track
|
|||
Bill Trenchard
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Nat Turner invest in?
Nat Turner invests primarily in Health Care, Software and Medical startups, most often at Seed and Series A stage. Most of the 80 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Nat Turner's check size?
Nat Turner typically joins rounds of $1.5M–$6.3M at Seed, $3M–$25M at Series A and $5M–$36M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Nat Turner participates in.
How do I contact Nat Turner?
Public channels for Nat Turner include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Nat Turner last invest?
The most recent investment recorded for Nat Turner closed in Feb 2023. Shizune tracks 80 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
